<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63776">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925937</url>
  </required_header>
  <id_info>
    <org_study_id>392219</org_study_id>
    <nct_id>NCT01925937</nct_id>
  </id_info>
  <brief_title>Atorvastatin/CoenzymeQ10 in Congestive Heart Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effect of addition of combination of
      Atorvastatin/CoenzymeQ10 to standard congestive heart failure (CHF) treatment versus
      addition of Atorvastatin alone on CHF outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in cardiac Ejection Fraction (EF)</measure>
    <time_frame>Baseline for the first time  and after 4 months for the second time</time_frame>
    <safety_issue>No</safety_issue>
    <description>For the determination of change in EF,cardiac EF was determined two times . Baseline :at  the beginning of study(before intervention)  and the second time after 4 months(after intervention).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association Function Class</measure>
    <time_frame>Baseline for the first time and after 4 months for the second time</time_frame>
    <safety_issue>No</safety_issue>
    <description>For the determination of change in New York Heart Association Function Class.it  was determined two times .Baseline:at  the beginning of study(before intervention)and the second time after 4 months(after intervention).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Coenzyme Q10 &amp; Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg Atorvastatin daily plus  100 mg Coenzyme Q10 pearl supplement twice daily for four months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin &amp; placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>Coenzyme Q10 &amp; Atorvastatin</arm_group_label>
    <arm_group_label>Atorvastatin &amp; placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <arm_group_label>Coenzyme Q10 &amp; Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for coenzyme Q10</intervention_name>
    <arm_group_label>Atorvastatin &amp; placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented Congestive hear failure

          -  Ejection Fraction less than 40 percent

          -  Compensated heart failure without hospital admission during previous three months

          -  No change in type and dose of medications in the last months

          -  New York Heart Association Function Class 2 to 4

        Exclusion Criteria:

          -  Acute coronary syndrome developing in the last month

          -  Active myocarditis

          -  Active pericarditis

          -  Uncontrolled hypertension

          -  Hepatic failure(Child B,C)

          -  Pulmonary failure

          -  Renal failure

          -  Heart failure with KILLIP classification 3 and 4
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masoud Pourmoghaddas, cardiologist</last_name>
    <role>Study Director</role>
    <affiliation>Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amin Nemati, MD</last_name>
    <phone>00989131009918</phone>
    <email>nemati@med.mui.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vice Chancellery for Research of Isfahan University of Medical Sciences, Isfahan, Iran</name>
      <address>
        <city>Isfahan</city>
        <zip>8174673461</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amin Nemati, MD</last_name>
      <phone>00989131009918</phone>
      <email>nemati@med.mui.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Javad Shahabi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 16, 2013</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Amin Nemati</investigator_full_name>
    <investigator_title>member of Isfahan Medical Students Research Committee</investigator_title>
  </responsible_party>
  <keyword>Coenzyme Q10</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>clinical trial</keyword>
  <keyword>congestive heart failure</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
